05.02.13
Charles River Laboratories
1Q Revenues: $291.2 million (+2%)
1Q Earnings: $25.8 million (-3%)
Comments: Research Models and Services (RMS) sales were flat at $182.5 million in the quarter. Excluding foreign exchange, RMS sales increased 1%. Preclinical Services (PCS) sales were $108.7 million, up 6%, driven by increased sales to large biopharma and mid-tier clients, primarily as a result of continued market share gains.
1Q Revenues: $291.2 million (+2%)
1Q Earnings: $25.8 million (-3%)
Comments: Research Models and Services (RMS) sales were flat at $182.5 million in the quarter. Excluding foreign exchange, RMS sales increased 1%. Preclinical Services (PCS) sales were $108.7 million, up 6%, driven by increased sales to large biopharma and mid-tier clients, primarily as a result of continued market share gains.